Mini Review

Role of cysteinyl-leukotrienes in the pathogenesis of nasal polyposis in patients with asthma

Masami Taniguchi*, Noritaka Higashi, Toyota Isii,

Kazuhiro Yamamoto, Haruhisa Mita, and Kazuo Akiyama

National Hospital Organization, Sagamihara National Hospital, Clinical Research Center, Sagamihara, Japan

Cysteinyl leukotrienes (CysLTs: leukotrienes C₄, D₄, and E₄) have long been implicated in the pathogenesis of allergic diseases such as asthma. CysLTs are potent bronchoconstrictors that have the additional effects of edema, mucous secretion, and eosinophilic accumulation, and airway remodeling. LTE₄ has been identified as a major metabolite of LTC₄, and urinary LTE₄ (U-LTE₄) is considered as the most reliable analytic parameter for monitoring the endogenous synthesis of CysLTs. From our extensive study of U-LTE₄ in adult asthma, we identified four factors for hyperleukotrienuria. These factors were aspirin-intolerance, eosinophilic nasal polyposis (ENP), vasculitis, and severe asthma. In ENP there is prominent infiltration of eosinophils in the sinus and polyp tissues, which is linked to adult asthma and aspirin-sensitivity, and ENP is the most important factor for overproduction of CysLTs in asthmatics. We demonstrated that there is a significant decrease in the U-LTE₄ concentration after the sinus surgery of asthmatics with and without aspirin intolerance. Recent studies reported that ENP tissue contain and produce a large amount of CysLTs, and there is a close relationship between CysLT production and eosinophil accumulation in ENP. These observations suggest that ENP is not only a local allergic disease, but also a systemic inflammatory disease with CysLT overproduction.

Rec.2/19/2007, Acc.5/7/2007, pp565-569

* Correspondence should be addressed to:

Masami Taniguchi, MD. PhD., Clinical Research Center, Sagamihara National Hospital, 18-1 Sakuradai, Sagamihara-Shi, Kanagawa, 228-8522, Japan. Phone: +81-42-742-8311, Fax: +81-42-742-7990, e-mail: m-taniguchi@sagamihara-hosp.gr.jp

Key words eosinophilic sinusitis, asthma, cysteinyl-leukotriene, nasal polyposis, aspirin-intolerant asthma

Cysteinyl leukotrienes, asthma, and eosinophilic inflammation

Leukotrienes (LTs) are among lipid mediators formed from the enzymatic metabolism of arachidonic acid (AA), and are the first biologic substances confirmed to have importance in the

clinical course of asthma and the physiologic changes of asthma. Both the cysteinyl leukotrienes (CysLTs), namely leukotriene C₄ (LTC₄), LTD₄, and LTE₄, and leukotriene B₄ (LTB₄) have long been implicated in the pathogenesis of allergic diseases such as asthma¹⁾. CysLTs are potent bronchoconstrictors that have the

Fig.1 Basal levels of urinary LTE₄ in patients with aspirin-intolerant asthma (AIA) and patients with aspirin-tolerant asthma (ATA).

Horizontal bars indicate geometric means.

* $p < 0.001$ compared with the control group; ** $p < 0.0001$ compared with the control group; ‡ $p < 0.0001$ compared with the ATA group. (Adapted from Kawagishi et al.¹⁵)

additional effects of edema, mucous secretion, and eosinophilic inflammation²⁻⁴). Recently, several reports demonstrated that CysLTs also have two other important effects, namely trafficking of eosinophils^{5,6} and induction of airway remodeling^{7,8}.

The CysLT₁ receptor is detected mainly on eosinophils, mast cells, and smooth muscle cells. Inhalation of LTE₄ has been shown to lead the infiltration of eosinophils into the lungs of asthmatic patients⁹). *In vitro* studies of the chemoattractant properties of CysLTs have shown only marginal effects of LTD₄¹⁰. If present, chemoattractant activity may occur through the secondary activation of the eosinophil chemoattractant and activator. In addition, a recent study suggests that CysLTs are important for prolonging eosinophil survival, which may also explain the increased-numbers of eosinophils after CysLTs inhalation. LTD₄ appears to have potency similar to that of granulocyte-macrophage colony-stimulating factor (GM-CSF) in this regard¹¹. LT receptor antagonists (LTRAs) and synthesis inhibitors were able to abolish the effect of eosinophil apoptosis, suggesting that this occurs in an autocrine manner through the CysLT₁ receptor¹¹.

Asthma with hyperleukotrieneuria

LTs are downstream products of the metabolism of cell or nuclear membrane phospholipids. In certain inflammatory cells

Fig.2 U-LTE₄ concentration in patients with aspirin-intolerant asthma (AIA) and patients with aspirin-tolerant asthma (ATA) classified according to clinical severity of asthma.

U-LTE₄ concentration is expressed by using the log scale. Patients with ATA and patients with AIA are denoted by closed square and an open circle, respectively. The dotted line indicates the mean level of U-LTE₄ in healthy control subjects.

* U-LTE₄ concentrations in patients with ATA with different clinical asthma severity levels were compared by using the Kruskal-Wallis test. (Adapted from Higashi et al.¹⁴)

e.g., eosinophils, mast cells, other inflammatory cells, degradation to AA by phospholipase A2 occurs at the nuclear membrane, which indicate the biologic functions of the LTs once they are formed¹⁻⁴). 5-lipoxygenase (5-LO) activation at the cytoplasmic or nuclear membrane then leads to the production of an unstable intermediate known as LTA₄, which can be further metabolized, depending on cell type, to LTB₄ or the cysLTs (LTC₄, LTD₄, and LTE₄). LTC₄ synthase metabolizes LTA₄ to LTC₄ via a glutathione transferase. LTC₄ is then rapidly metabolized to LTD₄ and LTE₄ through the enzymes gamma-glutamyl transpeptidase. LTC₄ and LTD₄ both have very short half-lives, whereas LTE₄ appears to be the most stable of the three, with the longest half-life¹².

LTE₄ has been identified as a major metabolite of LTC₄, recently, urinary LTE₄ (U-LTE₄) has been considered as the most reliable analytic parameter for monitoring the endogenous synthesis of CysLT¹³. Previous studies showed that U-LTE₄ concentration is useful for demonstrating CysLT production *in vivo* during allergen challenge and an acute attack of asthma¹³. More-

Fig.3 U-LTE₄ (A) and eosinophil derived neurotoxin (EDN,B) concentrations in patients with Churg-Strauss syndrome (CSS), noneosinophilic vasculitis (VD), rheumatoid arthritis (RA), and healthy control (HC).

U-LTE₄ concentration is expressed by using the log scale. The horizontal bars indicate medians.

* $p < 0.05$; † $p < 0.01$. (Adapted from Higashi et al.¹⁷⁾)

over, even in a clinically stable condition, U-LTE₄ concentration in patients with aspirin-intolerant asthma (AIA) is significantly higher than that in patients with aspirin-tolerant asthma (ATA)^{14,15}. Recently, we have evaluated the clinicopathological factors that were associated with the increase in U-LTE₄ concentration in asthmatics and we confirmed that U-LTE₄ concentration in AIA patients was significantly higher than those in ATA patients (Fig.1). According to asthma severity, ATA patients with severe asthma and AIA patients with poor pulmonary function showed a significant increase in U-LTE₄ concentration, but the extent of increase in U-LTE₄ concentration was not large (Fig.2)¹⁴. Moreover, we have demonstrated for the first time that nasal polyposis is one of the most important factors indicating hyperleukotrienuria¹⁴. Recently, we have determined another clinicopathological factor for hyperleukotrienuria in patients with

Fig.4 The four clinicopathological factors associated with hyperleukotrienuria in adult asthmatics.

adult asthma. Churg-Strauss syndrome (CSS) is characterized by the presence of asthma, eosinophilia, and small-vessel vasculitis with granuloma¹⁶. The natural history of CSS is, first, the appearance of eosinophilic rhinosinusitis, followed several years later by the development of difficult asthma with marked peripheral blood eosinophilia, and finally the development of systemic vasculitis¹⁶. We have demonstrated that U-LTE₄ concentration is elevated in the acute phase of CSS¹⁷. However, U-LTE₄ concentration significantly increases in not only eosinophilic vasculitis, including CSS, but also noneosinophilic vasculitis (Fig.3)¹⁷.

From these observations, we postulate that the four clinicopathological factors associated with hyperleukotrienuria in adult asthmatics were firstly aspirin-intolerance, secondly nasal polyposis, thirdly CSS, and finally (this is not so important factor) severe asthma (Fig.4).

Role of cysteinyl-leukotrienes in the pathogenesis of nasal polyposis

Nasal polyps are edematous semitranslucent masses in the nasal and paranasal cavities, mostly originating from the mucosal linings of the sinuses and prolapsing into the nasal cavities. Eosinophilic nasal polyposis (ENP), in which there are prominent infiltration of eosinophils and submucosal edema, is linked to comorbidities such as nonatopic asthma, adult-onset asthma, aspirin intolerance, or may represent a part of a systemic disease such as CSS^{16,18}. Despite sinus surgery or intensive steroid therapy, the recurrence rate of ENP in patients with asthma is very high, and the pathogenesis of ENP has not been clarified¹⁸.

For the first time, we found that the U-LTE₄ concentration is significantly high even in ENP patients without aspirin-sensitiv-

Fig.5 U-LTE₄ concentration in patients with eosinophilic nasal polyposis (ENP) and those with normal sinuses.

U-LTE₄ concentration is expressed by using the log scale. The horizontal bars indicate medians. (Adapted from Higashi et al.¹⁴)

ity (Fig.5). Next we confirmed the changes in U-LTE₄ concentration after endoscopic sinus surgery without changing medication. We demonstrated that U-LTE₄ concentrations significantly decreased after the sinus surgery in both AIA and ATA (Fig.6)¹⁴. Steinke et al. reported that CysLT concentrations in ENP tissues are significantly higher than those in noneosinophilic nasal polyp tissues¹⁹. They also demonstrated that the presence of CysLTs in ENP is associated with an increased expression level of LTC₄ synthase mRNA¹⁹. Perez-Novo et al. confirmed that the concentrations of CysLTs, eosinophil cationic protein (ECP), and the expression level of LTC₄ synthase mRNA in ENP tissues were significantly higher than those in the tissue with sinusitis without polyps²⁰. From our findings and recent reports^{19,20}, we conclude ENP tissues contain and produce large amounts of CysLTs, and that there is a close correlation between CysLT production and eosinophil accumulation in ENP. CysLTs have several inflammatory effects on eosinophils, which are not only activation, but also the effect of trafficking and inhibition of apoptosis^{5,6}. Eosinophils are among the CysLTs producing-cells, and also have the CysLT₁ receptor. The phenomena of eosinophil accumulation and CysLTs overproduction in ENP seem to comprise a malignant cycle in allergic inflammation.

References

- 1) Henderson WR Jr: The role of leukotrienes in inflammation. *Ann Intern Med*, 121(9): 684-697, 1994.

Fig.6 A significant decrease in U-LTE₄ concentration between before and after the endoscopic sinus surgery without changing medication. The horizontal bars indicate medians. (Adapted from Higashi et al.¹⁴)

- 2) Dahlen SE: Lipid mediator pathways in the lung: leukotrienes as a new target for the treatment of asthma. *Clin Exp Allergy*, 28(Suppl 5): 141-146, 1998.
- 3) Wenzel SE: The role of leukotrienes in asthma. *Prostaglandins Leukot Essent Fatty Acids*, 69(2-3): 145-155, 2003.
- 4) Drazen JM: Leukotrienes in asthma. *Adv Exp Med Biol*, 525: 1-5, 2003.
- 5) Nagata M, Saito K: The roles of cysteinyl leukotrienes in eosinophilic inflammation of asthmatic airways. *Int Arch Allergy Immunol*, 131(Suppl 1): 7-10, 2003.
- 6) Woodward DF, Krauss AH-P, Nieves AL, Spada CS: Studies on leukotriene D₄ as an eosinophil chemoattractant. *Drugs Exp Clin Res*, 17(12): 543-548, 1991.
- 7) Panettieri RA: Cellular and molecular mechanisms regulating airway smooth muscle proliferation and cell adhesion molecule expression. *Am J Respir Crit Care Med*, 158(5 Pt 3): S133-140, 1998.
- 8) Kotaru C, Schoonover KJ, Trudeau JB, Huynh ML, Zhou X, Hu H, Wenzel SE: Regional fibroblast heterogeneity in the lung: implications for remodeling. *Am J Respir Crit Care Med*, 173(11): 1208-1215, 2006.
- 9) Laitinen LA, Laitinen A, Haahtela T, Vilkkä V, Spur BW, Lee TH: Leukotriene E₄ and granulocytic infiltration into asthmatic airways. *Lancet*, 341: 989-990, 1993.
- 10) Mulder A, Gauvreau GM, Watson RM, O'byrne PM: Effect of inhaled leukotriene D₄ on airway eosinophilia and air-

way hyperresponsiveness in asthmatic subjects. *Am J Respir Crit Care Med*, 159: 1562-1567, 1999.

- 11) Lee E, Robertson T, Smith J, Kilfeader S: Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. *Am J Respir Crit Care Med*, 161: 1881-1886, 2000.
- 12) Zakrzewski JT, Sampson AP, Evans JM, Barnes NC, Piper PJ, Costello JF: The biotransformation in vitro of cysteinyl leukotrienes in blood of normal and asthmatic subjects. *Prostaglandins*, 37: 425-444, 1989.
- 13) Dahlen SE, Kumlin M: Can asthma be studied in the urine? *Clin Exp Allergy*, 28(2): 129-133, 1998.
- 14) Higashi N, Taniguchi M, Mita H, Kawagishi Y, Ishii T, Higashi A, Osame M, Akiyama K: Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. *J Allergy Clin Immunol*, 113: 227-283, 2004.
- 15) Kawagishi Y, Mita H, Taniguchi M, Maruyama M, Oosaki R, Higashi N, Kashii T, Kobayashi M, Akiyama K: Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. *J Allergy Clin Immunol*, 109(6): 936-942, 2002.
- 16) Taniguchi M, Tsurikisawa N, Higashi N, Saito N, Mita H, Mori A, Sakakibara H, Akiyama K: Treatment for Churg-Strauss syndrome: induction of remission and efficacy of intravenous immunoglobulin therapy. *Allergol Int*, 56(2): 97-103, 2007.
- 17) Higashi N, Mita H, Taniguchi M, Tsurikisawa N, Higashi A, Ozawa Y, Tohma S, Arimura K, Akiyama K: Urinary eicosanoid and tyrosine derivative concentration in patients with vasculitides. *J Allergy Clin Immunol*, 114: 1353-1358, 2004.
- 18) Slavin RG, Spector SL, Bernstein IL, Kaliner MA, Kennedy DW, Virant FS, Wald ER, Khan DA, Blessing-Moore J, Lang DM, Nicklas RA, Oppenheimer JJ, Portnoy JM, Schuller DE, Tilles SA, Borish L, Nathan RA, Smart BA, Vandewalker ML: The diagnosis and management of sinusitis: a practice parameter update. *J Allergy Clin Immunol*, 116(6 Suppl): S13-S47, 2005.
- 19) Steinke JW, Bradley D, Arango P, Crouse CD, Frierson H, Kountakis SE, Kraft M, Borish L: Cysteinyl leukotriene expression in chronic hyperplastic sinusitis-nasal polyposis: importance to eosinophilia and asthma. *J Allergy Clin Immunol*, 111(2): 342-349, 2003.
- 20) Perez-Novo CA, Watelet JB, Claeys C, Van Cauwenberge P, Bachert C: Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. *J Allergy Clin Immunol*, 115(6): 1189-1196, 2005.